Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 1/20 | 0.78 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.78 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.78 |
| ▸ | CTSL | P07711 | 11/20 | 0.73 |
| ▸ | CTSB | P07858 | 7/20 | 0.73 |
| ▸ | CTSK | P43235 | 6/20 | 0.70 |
| ▸ | CTSS | P25774 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971981 | 1.00 | PSMB1 (0.78) | PSMB1PSMB5PSMB2CTSLCTSB | |
| SCHEMBL3054703 | 1.00 | PSMB1 (0.78) | PSMB1PSMB5PSMB2CTSLCTSB | |
| SCHEMBL7710728 | 1.00 | PSMB1 (0.78) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL7862424 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL14579851 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL5062219 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL14514061 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL13436259 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL2522088 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL2535252 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551512-A | Use of compounds or compositions comprising NLRP1 inflammatory body activation inhibitors for the treatment of airway inflammation in humans | 南洋理工大学 | 2022-12-30 | — | — | CN | claimed |
| CN-113272294-A | 2, 6-bis (((1H-benzo [ D ] imidazol-2-yl) thio) methyl) pyridine and N2, N6-dibenzylpyridine-2, 6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer | 雅典学院生物医学研究基金会 | 2021-08-17 | — | — | CN | claimed |
| CN-118215461-A | Compositions and methods for reducing pigmentation | 总医院公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117355333-A | Combination comprising anti-TM 4SF1 antibody and immunotherapeutic agent and method of use thereof | 安吉克公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-115551512-A | Use of compounds or compositions comprising NLRP1 inflammatory body activation inhibitors for the treatment of airway inflammation in humans | 南洋理工大学 | 2022-12-30 | — | — | CN | disclosed |
| CN-113272294-A | 2, 6-bis (((1H-benzo [ D ] imidazol-2-yl) thio) methyl) pyridine and N2, N6-dibenzylpyridine-2, 6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer | 雅典学院生物医学研究基金会 | 2021-08-17 | — | — | CN | disclosed |
| CN-112359018-A | Methods and compositions for regenerating hair cells and/or supporting cells | 麻省眼耳医院 | 2021-02-12 | — | — | CN | disclosed |
| CN-105641700-B | Means and methods for combating muscle disorders | 莱顿教学医院 | 2021-01-01 | — | — | CN | disclosed |
| CN-104869987-B | Methods and compositions for regenerating hair cells and/or supporting cells | 麻省眼耳医院 | 2020-10-16 | — | — | CN | disclosed |
| US-9128081-B2 | TDP-43-storing cell model | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2015-09-08 | — | — | US | disclosed |
| EP-2272955-B1 | TDP-43-STORING CELL MODEL | TOKYO METROPOLITAN INST MEDICAL SCIENCE (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8715643-B2 | TDP-43-storing cell model | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2014-05-06 | — | — | US | disclosed |
| US-20140099660-A1 | TDP-43-STORING CELL MODEL | TOKYO METROPOLITIAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2014-04-10 | — | — | US | disclosed |
| US-20110034447-A1 | TDP-43-STORING CELL MODEL | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2272955-A1 | TDP-43-STORING CELL MODEL | Tokyo Metropolitan Organization for Medical Research (JP) | 2011-01-12 | — | — | EP | disclosed |